Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
Iridex Corp (IRIX) Form 4: The reporting person, Romeo R. Dizon (CFO), made a purchase of 625 shares of Iridex common stock on 08/29/2025 at a price of $1.37 per share. Following the transaction, Mr. Dizon beneficially owned 52,375 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported multiple open-market purchases totaling 1,005 shares on 08/28/2025. The transactions executed at prices between $1.325 and $1.36 per share increased his direct beneficial ownership from 50,745 shares to 51,750 shares. Individual purchases reported: 50 shares at $1.33, 200 shares at $1.325, 250 shares at $1.35 and 505 shares at $1.36. The Form 4 was signed by an attorney-in-fact on 08/29/2025. No derivative transactions were reported and no additional explanatory text was provided.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Iridex Corp Chief Financial Officer Romeo R. Dizon reported purchases of common stock on 08/26/2025. The filing shows two open-market buys: 750 shares at $1.26 and 250 shares at $1.25, for a total of 1,000 shares acquired. Following these transactions his beneficial ownership increased to 49,745 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and contains no derivative transactions or additional explanatory notes.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported four separate purchases of common stock on 08/25/2025. Each transaction (code P) was for 250 shares at prices of $1.25, $1.245, $1.24 and $1.2454, increasing his reported beneficial ownership sequentially to 47,995, 48,245, 48,495 and 48,745 shares. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Insider purchases increased stake in IRIDEX Corp. Romeo R. Dizon, the company's Chief Financial Officer, acquired a total of 1,000 shares of IRIDEX common stock on 08/22/2025 in three open-market transactions priced at $1.21, $1.22 and $1.23 per share. Following these purchases his reported beneficial ownership rose from 46,995 to 47,745 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Iridex Corp (IRIX) Form 4: Chief Financial Officer Romeo Dizon reported two purchases on 08/21/2025 totaling 2,000 shares of common stock. The first purchase was 1,000 shares at $1.27 and the second was 1,000 shares at $1.22. Beneficial ownership increased to 46,745 shares following the transactions. The form was signed 08/22/2025 by an attorney-in-fact.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases on 08/20/2025. He acquired 825 shares at $1.17 and 175 shares at $1.25, bringing his reported beneficial ownership to 44,745 shares following the transactions. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
The filing lists Mr. Dizon's address in Mountain View, CA, and indicates the report was filed by one reporting person. No derivative transactions or additional explanations were provided in the filing.
Iridex Corp (IRIX) reported insider purchases by Chief Financial Officer Romeo R. Dizon on 08/19/2025. The reporting person acquired a total of 1,500 shares through three purchase transactions: 1,000 shares at $1.18, 500 shares at $1.16, and an aggregate line showing 1,500 shares at $1.1593, bringing his direct holdings to 43,745 shares after the trades. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
William M. Moore, a director of Iridex Corporation (IRIX), reported purchases of the company’s common stock on 08/18/2025. The filing shows he acquired 12,024 shares at a weighted average price of $1.1834 per share (prices ranged from $1.175 to $1.1899). After the purchases, Mr. Moore directly beneficially owned 200,674 shares. The filing also discloses indirect holdings of 69,300 shares held by his spouse and 30,026 shares held in two trusts where he and his spouse serve as trustees/tenants in common. The Form 4 was signed on behalf of Mr. Moore by an attorney-in-fact on 08/19/2025.